Skip to Content

We invite you to try out our new beta eCFR site at https://ecfr.federalregister.gov. We’ve made big changes to make the eCFR easier to use. Be sure to leave feedback using the 'Feedback' button on the bottom right of each page!

Notice

Bulk Manufacturer of Controlled Substances Application: SPECGX LLC

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 26943

AGENCY:

Drug Enforcement Administration, Justice.

ACTION:

Notice of application.

SUMMARY:

SPECGX LLC, has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES:

Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 19, 2021. Such persons may also file a written request for a hearing on the application on or before July 19, 2021.

ADDRESSES:

Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.33(a), this is notice that on February 5, 2021, SPECGX LLC, 3600 N 2nd Street, Saint Louis, Missouri 63147, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substanceDrug codeSchedule
Gamma Hydroxybutyric Acid2010I
Tetrahydrocannabinols7370I
Codeine-N-oxide9053I
Dihydromorphine9145I
Difenoxin9168I
Morphine-N-oxide9307I
Normorphine9313I
Alphamethadol9605I
Betamethadol9609I
Norlevorphanol9634I
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)9821I
Butyryl Fentanyl9822I
Fentanyl related-compounds as defined in 21 CFR 1308.11(h)9850I
Amphetamine1100II
Methamphetamine1105II
Lisdexamfetamine1205II
Methylphenidate1724II
Nabilone7379II
ANPP (4-Anilino-N-phenethyl-4-piperidine)8333II
Codeine9050II
Dihydrocodeine9120II
Oxycodone9143II
Hydromorphone9150II
Diphenoxylate9170II
Ecgonine9180II
Hydrocodone9193II
Levorphanol9220II
Meperidine9230II
Meperidine intermediate-A9232II
Meperidine intermediate-B9233II
Meperidine intermediate-C9234II
Methadone9250II
Methadone intermediate9254II
Dextropropoxyphene, bulk (non-dosage forms)9273II
Morphine9300II
Oripavine9330II
Thebaine9333II
Opium tincture9630II
Opium, powdered9639II
Oxymorphone9652II
Noroxymorphone9668II
Alfentanil9737II
Remifentanil9739II
Sufentanil9740II
Tapentadol9780II
Fentanyl9801II

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers. In reference to dug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture this drug as synthetic. No other activities for these drug codes are authorized for this registration.

Start Signature

William T. McDermott,

Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2021-10412 Filed 5-17-21; 8:45 am]

BILLING CODE P